Bicycle Therapeutics Just Torched Its Best Shot at a Blockbuster

And the trial design made that even harder. Duravelo-2 used chemotherapy as its control arm instead of Padcev. That's a strange choice when regulators increasingly want to see head-to-head comparisons against the best available treatment. Meanwhile, competitor Innate Pharma took a more pragmatic approach, pursuing accelerated approval for its own Nectin-4 drug specifically in patients who had already failed on Padcev.

Bicycle was trying to kick down the front door. Everyone else was looking for the side entrance.

What's Left in the Tank

So Bicycle torched its lead program. What now?

The Duravelo-2 trial isn't completely dead; it's being converted to a smaller randomized Phase 2 study. But Duravelo-3 (breast cancer) and Duravelo-4 (lung cancer) are done. Patients already enrolled can finish treatment, but no new ones are coming in.

The company is betting its future on nuzefatide pevedotin (BT5528), a bicycle toxin conjugate targeting a different protein called EphA2, currently in Phase 1/2 trials for advanced solid tumors and pancreatic cancer. There's also a pivot toward radioconjugates, which swap the toxic chemical payload for a radioactive one. Think of it as switching from a guided missile to a guided nuclear warhead (at a microscopic scale, of course).

There's a catch, though. Previous attempts to target EphA2 by other companies have been derailed by toxicity issues. Bicycle believes its smaller bicycle peptide platform can avoid those problems, but the jury is still out.

The Money Math

Let's talk numbers, because they tell an interesting story.

Bicycle ended 2025 with $628 million in cash. That sounds like a lot, and it is. But the company burned through $219 million in net losses last year, up from $169 million in 2024. R&D spending alone hit $240 million, ballooning from $173 million the year before. At that rate, the cash pile was on track to last until roughly 2028.

The restructuring changes that math significantly. By cutting operating expenses in half, Bicycle says it can stretch that runway all the way to 2030. That's a meaningful difference: four years of breathing room instead of two. The one-time cost of severance runs about $8 million, which is pocket change relative to the savings.

Collaboration revenue did grow nicely in 2025, hitting $72.6 million compared to $35.3 million the year before. But when you're losing $219 million annually, revenue growth alone doesn't solve the problem.

A Pioneer Struggling to Keep Up

Bicycle Therapeutics essentially invented the bicycle toxin conjugate category. The company's whole pitch was that its tiny constrained peptides could do what bulky antibodies couldn't: penetrate tumors faster, clear the body quicker, and deliver payloads more precisely. It was an elegant idea that attracted hundreds of millions in funding.

But pioneering a field and winning in it are two different things. The competitive landscape has shifted dramatically. More biotech and pharmaceutical companies are building peptide-based targeting systems. Padcev raised the efficacy bar in bladder cancer to a level zelenectide couldn't match. And regulators, burned by past accelerated approvals that didn't pan out, are demanding more rigorous evidence.

The appointment of Jennifer Perry as the new Chief Operating Officer signals that Bicycle is trying to professionalize its operations for a leaner era. Her job won't be glamorous: manage the wind-down, protect the remaining pipeline, and make $628 million last until something works.

The Bigger Picture

Bicycle's story is a cautionary tale for the entire clinical-stage oncology space. Having a novel technology platform isn't enough. Having promising early data isn't enough. You need a clear regulatory path, a competitive positioning that makes sense, and the discipline to kill programs before they drain you dry.

Bicycle got two out of three. It had the novel platform and some promising signals. But it spent years and hundreds of millions chasing a bladder cancer indication where Padcev had already planted its flag. By the time regulators said "this isn't going to work," the company had already built an entire organization around a program it now has to abandon.

The silver lining? Bicycle still has cash, a differentiated platform, and a backup candidate in BT5528. The radioconjugate pivot could open entirely new therapeutic possibilities. But the company that once looked like it might redefine drug conjugates is now in survival mode, hoping its second act is better than its first.

In biotech, sometimes the most important drug is the one you stop making.

The Eye Drug That Just Can't Take a Hint

Aldeyra Therapeutics just received its third FDA rejection for dry eye drug reproxalap, with regulators once again citing inconsistent efficacy data. The stock plunged over 70%, and Wall Street is running out of patience for a drug that keeps failing the same test.